Clinical trial flops have become the norm for Alzheimer’s disease treatments, despite the billions put into research for the memory-robbing disorder. But a new Lexington, MA-based startup called Alzheon sees opportunity in all of those high-profile failures of the past. Its belief is that these failures have left behind a treasure trove of clinical data, and stalled drug candidates, that can be plucked, refined, and developed to work for more specific groups of patients.

As quoted from xconomy.com.  Read the full article here